These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 24605355

  • 1. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course.
    Wu R, Zippin JH, Magro C.
    Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355
    [Abstract] [Full Text] [Related]

  • 2. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH, Shane RB, Geng Y, Showe LC, Everetts SE, Presky DH, Wysocka M, Moore JS, Rook AH.
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [Abstract] [Full Text] [Related]

  • 3. Double-positive CD4/CD8 mycosis fungoides: a rarely reported immunohistochemical profile.
    Tournier E, Laurent C, Thomas M, Meyer N, Viraben R, Brousset P, Lamant L.
    J Cutan Pathol; 2014 Jan; 41(1):58-62. PubMed ID: 24134789
    [Abstract] [Full Text] [Related]

  • 4. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
    Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Steitz J, Roszkiewicz J, Bieber T, Tüting T.
    Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
    [Abstract] [Full Text] [Related]

  • 5. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
    van der Fits L, Rebel HG, Out-Luiting JJ, Pouw SM, Smit F, Vermeer KG, van Zijl L, Tensen CP, Weijer K, Vermeer MH.
    Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
    [Abstract] [Full Text] [Related]

  • 6. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS, Newton SM, Wysocka M, Troxel AB, Hess SD, Richardson SK, Lin JH, Benoit BM, Kasprzycka M, Wasik MA, Rook AH.
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
    van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, Zoutman WH, Willemze R, Tensen CP, Vermeer MH.
    J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
    [Abstract] [Full Text] [Related]

  • 8. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
    Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, Abuzahra F, Bowman E, Roszkiewicz J, Bieber T, Tüting T.
    Br J Dermatol; 2005 Feb; 152(2):258-64. PubMed ID: 15727636
    [Abstract] [Full Text] [Related]

  • 9. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
    Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, Géraud C, Kempf W, Assaf C, Ortonne N, Battistella M, Bagot M, Knobler R, Quaglino P, Arheiliger B, Santucci M, Jansen P, Vermeer MH, Willemze R.
    Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
    [Abstract] [Full Text] [Related]

  • 10. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
    Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R.
    Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
    [Abstract] [Full Text] [Related]

  • 11. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
    Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH.
    J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
    [Abstract] [Full Text] [Related]

  • 12. Autopsy case of CD4/CD8 cutaneous T-cell lymphoma presenting disseminated pagetoid reticulosis with aggressive granulomatous invasion to the lungs and pancreas.
    Shiozawa E, Shiokawa A, Shibata M, Nakada T, Yamochi-Onizuka T, Saito B, Takaba E, Iijima M, Takimoto M, Ota H.
    Pathol Int; 2005 Jan; 55(1):32-9. PubMed ID: 15660701
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a malignant T-cell line established from a rare case of CD8+ CD56+ Sézary syndrome.
    Shimauchi T, Yagi H, Sasada K, Kito Y, Ito T, Hirakawa S, Tokura Y.
    Br J Dermatol; 2013 Apr; 168(4):885-7. PubMed ID: 23013154
    [No Abstract] [Full Text] [Related]

  • 14. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
    Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Santos AH, Fonseca S, Balanzategui A, Justica B, Orfao A.
    Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
    [Abstract] [Full Text] [Related]

  • 15. Sezary syndrome: cutaneous immunoperoxidase double-labeling technique demonstrates CD4/CD8 ratio non-specificity.
    Balfour EM, Glusac EJ, Heald P, Talley LL, Smoller BR.
    J Cutan Pathol; 2003 Aug; 30(7):437-42. PubMed ID: 12859741
    [Abstract] [Full Text] [Related]

  • 16. mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome.
    Bénard A, Cavaillès P, Boué J, Chapey E, Bayry J, Blanpied C, Meyer N, Lamant L, Kaveri SV, Brousset P, Dietrich G.
    J Invest Dermatol; 2010 May; 130(5):1337-44. PubMed ID: 20107485
    [Abstract] [Full Text] [Related]

  • 17. The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.
    Miyashiro D, Souza BCE, Torrealba MP, Manfrere KCG, Sato MN, Sanches JA.
    Int J Mol Sci; 2022 Jan 15; 23(2):. PubMed ID: 35055124
    [Abstract] [Full Text] [Related]

  • 18. [Sézary syndrome with two lymphocyte subpopulations expressing either CD4+/CD8- or CD4-/CD8+].
    Kodama K, Kataoka Y, Tamura T, Arai J, Matsuo T.
    Rinsho Ketsueki; 1997 Nov 15; 38(11):1238-41. PubMed ID: 9423345
    [Abstract] [Full Text] [Related]

  • 19. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
    Narducci MG, Tosi A, Frezzolini A, Scala E, Passarelli F, Bonmassar L, Monopoli A, Accetturi MP, Cantonetti M, Antonini Cappellini GC, De Galitiis F, Rosato A, Picozza M, Russo G, D'Atri S.
    Front Immunol; 2020 Nov 15; 11():579894. PubMed ID: 33072126
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-7 is a growth factor for Sézary lymphoma cells.
    Dalloul A, Laroche L, Bagot M, Mossalayi MD, Fourcade C, Thacker DJ, Hogge DE, Merle-Béral H, Debré P, Schmitt C.
    J Clin Invest; 1992 Sep 15; 90(3):1054-60. PubMed ID: 1381718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.